BioSpace News Archive

Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that additional clinical and biomarker research on its lead product candidate, currently being evaluated as a potential treatment for nonalcoholic steatohepatitis (NASH), will be shared via a poster presentation at The International Liver Congress™ 2021 (EASL),

Sonata Scientific LLC, a developer of advanced air purification and antimicrobial products, has been awarded an U.S. Environmental Protection Agency (EPA) Small Business Innovation Research (SBIR) grant for $100,000 to conduct research and development (R&D) work on reducing the transmission of COVID-19 by contaminated surfaces.

Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings

Detailed results from Phase 2b study of roflumilast foam in scalp and body psoriasis featured in late-breaking oral presentation Data demonstrate roflumilast foam was well-tolerated and improved scalp and body psoriasis as early as two weeks after treatment initiation Four additional posters feature data that support roflumilast foam for the treatment of seborrheic dermatitis and roflumilast cream for mild-to- severe chronic plaque psoriasis

Left atrial appendage is a common site for thrombus formation. LAA is multi-lobed and can vary in orifice size and length.

Interleukin-2 is a novel procedure that has shown promising results in treatment of autoimmune disorder, blood cancer, ovarian cancer and renal cell.

Catheter is a flexible tube which is inserted through a narrow opening into a body cavity, particularly the bladder, for removing fluid.

Disposable elastomeric pumps are designed for infusion of low molecular weight drugs such as chemotherapy, anesthetic, analgesic and antibiotic drugs

ChenMed, a national leader in primary care for underserved seniors, announced that Atlanta resident James B. “Buck” McCabe has joined its Board of Directors to help the company keep strengthening its culture in a period of sustained hyper growth.

- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is no U.S. Food and Drug Administration (FDA)-approved treatment.